about
Role of transglutaminase 2 in celiac disease pathogenesisHighly efficient gluten degradation by lactobacilli and fungal proteases during food processing: new perspectives for celiac diseaseA non-human primate model for gluten sensitivity.Parallels between pathogens and gluten peptides in celiac sprueToward the assessment of food toxicity for celiac patients: characterization of monoclonal antibodies to a main immunogenic gluten peptide.Identification of gliadin-binding peptides by phage display.Degradation of coeliac disease-inducing rye secalin by germinating cereal enzymes: diminishing toxic effects in intestinal epithelial cells.Identification of Rothia bacteria as gluten-degrading natural colonizers of the upper gastro-intestinal tract.Defining primary bile acid diarrhea: making the diagnosis and recognizing the disorder.Novel therapies for coeliac diseaseReview article: coeliac disease, new approaches to therapy.Prevention measures and exploratory pharmacological treatments of celiac disease.Medical nutrition therapy: use of sourdough lactic acid bacteria as a cell factory for delivering functional biomolecules and food ingredients in gluten free breadThe effects of reduced gluten barley diet on humoral and cell-mediated systemic immune responses of gluten-sensitive rhesus macaques.Discerning the role of Bacteroides fragilis in celiac disease pathogenesis.Induction of antigen-specific tolerance by oral administration of Lactococcus lactis delivered immunodominant DQ8-restricted gliadin peptide in sensitized nonobese diabetic Abo Dq8 transgenic mice.Possible drug targets for celiac disease.Randomised clinical study: Aspergillus niger-derived enzyme digests gluten in the stomach of healthy volunteers.Coeliac disease: current approach and future prospects.Investigational therapies for celiac disease.Enzymatic strategies to detoxify gluten: implications for celiac disease.Proteomic analysis in allergy and intolerance to wheat products.TG2, a novel extracellular protein with multiple functions.Celiac disease in pediatric patients with autoimmune hepatitis: etiology, diagnosis, and management.The interaction of dietary fibres with disulphide bonds (S-S) and a potential strategy to reduce the toxicity of the gluten proteins in coeliac disease.IL-17 producing T cells in celiac disease: angels or devils?Prolyl-specific peptidases for applications in food protein hydrolysis.Selected Probiotic Lactobacilli Have the Capacity To Hydrolyze Gluten Peptides during Simulated Gastrointestinal Digestion.Systematic review: patient-reported outcome measures in coeliac disease for regulatory submissions.Oral nucleic acid therapy using multicompartmental delivery systems.Screening sourdough samples for gliadin-degrading activity revealed Lactobacillus casei strains able to individually metabolize the coeliac-disease-related 33-mer peptide.Oral proteases: a new approach to managing coeliac disease.Celiac disease: Alternatives to a gluten free diet.Coeliac disease: between "pizza" and ethics.Enzymatic detoxification of gluten by germinating wheat proteases: implications for new treatment of celiac disease.Identification and characterization of intestinal lactobacilli strains capable of degrading immunotoxic peptides present in gluten.Significant Hydrolysis of Wheat Gliadin by Bacillus tequilensis (10bT/HQ223107): a Pilot Study.Cross-Talk Between Gluten, Intestinal Microbiota and Intestinal Mucosa in Celiac Disease: Recent Advances and Basis of Autoimmunity
P2860
Q28262529-CBBEDE3E-EA19-4B2A-84BD-5A7166B1BB42Q33285135-BD962F60-EFC8-4809-89AE-DB610B4BC680Q33320524-349A190E-C190-4E1B-9FAD-CFB867D8E6CBQ33329537-3697FAE2-E7C6-4A13-834E-8DE423872EB7Q33338495-2C68C1F7-D4D3-4C57-AD44-D1B93EC2A4ECQ33823074-BD1C6AD4-552C-487D-B418-83878E3C5136Q34022801-BBE75794-E6FA-4590-93FC-11B10131E101Q34034638-7F3D4150-50FA-4592-9898-4B36AB95781DQ34142506-1B1473D5-4BCE-4BA9-808B-D99CCF206686Q34170574-6070A90E-BBB0-47C5-9CC4-F26E5A82E90CQ34253519-F584CC5B-4DF4-4BD2-AFFA-544A5F1A8F48Q34623902-6BE21BE3-A6C5-4128-928A-BF5D94AA35BBQ34633010-782C58AA-05F2-4847-89C4-D80C70ED251AQ35227859-25B13FB1-92C9-4297-A45F-F78ADB14DD85Q36186148-07DA322B-452A-44D6-89DE-40AE32108E0CQ36344875-AB790417-206F-4AEB-A05A-73322676A826Q36539486-45BE1736-BA2E-400F-985E-923286486F61Q37275552-0C56B4ED-5EFB-4857-952C-A8CAADA302CBQ37368419-FDB5EC86-0F9D-4DAD-9929-83B9D94E0F40Q37638684-6BB49AC2-3B39-4907-B615-0BF345DEF5B3Q37806959-6108AAE1-F586-4D96-92EE-6B9F3AB00C99Q37844154-97753FED-F55A-42AA-9F00-D4AE9F148C9CQ37912042-415E4D05-DECE-4CBA-9644-C6F249FB10E3Q37965669-A8F3FC93-F2B9-44D5-972F-713892B4BC47Q38012150-AADCC0FA-F577-4859-A852-6A5F79B11E15Q38138107-79D9A680-793C-438C-9F2C-9A74B281DB19Q38560146-1D05F4BA-1369-41A3-B59B-0ED0076F439CQ38788626-4B8BF9A4-8494-410B-B17E-78A1E3D7B729Q38878748-0DCAC5D9-B668-4C18-9078-CB71B0AAD4DAQ39330117-FEC64780-691D-4673-9D51-0CFDC2F16611Q39883542-75E25448-3EEB-4052-9C19-8680B9E3A747Q42061479-BB63852D-0ED1-49D3-B892-BB8F5BD21FE7Q42730481-EED979C7-5AB3-469A-9923-09F47DDC337FQ42835973-80F82017-27A9-40E7-AB29-D4AB73E361CFQ46057460-2BBB44AC-961A-4C46-A00D-67979C5165C7Q46817256-D2C570DF-1BCA-4619-8660-0030C394AA78Q47743038-F0CDF623-48E2-4D9D-BC67-4DDB41C2ED42Q59137735-7360855E-6914-42E3-88E8-DFEF3B91FF14
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Future therapeutic options for celiac disease.
@ast
Future therapeutic options for celiac disease.
@en
type
label
Future therapeutic options for celiac disease.
@ast
Future therapeutic options for celiac disease.
@en
prefLabel
Future therapeutic options for celiac disease.
@ast
Future therapeutic options for celiac disease.
@en
P2860
P356
P1476
Future therapeutic options for celiac disease.
@en
P2093
Chaitan Khosla
Ludvig M Sollid
P2860
P2888
P304
P356
10.1038/NCPGASTHEP0111
P407
P577
2005-03-01T00:00:00Z